ArticleMicrobiology spectrum2021
Clinical Impact of the Expanded BioFire Blood Culture Identification 2 Panel in a U.S. Children's Hospital.
Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Performance of BioFire Blood Culture Identification 2 Panel (BCID2) for the detection of bloodstream pathogens and their associated resistance markers: a systematic review and meta-analysis of diagnostic test accuracy studies.BMC infectious diseases · 2022Pooled it
- Implementation of multiplex PCR-based blood culture identification among hospitalized pediatric patients at a tertiary care center.Microbiology spectrum · 2026Article
- Article
- Rapid Diagnostics and Rapid Antimicrobial Susceptibility Testing for Bloodstream Infections: A Narrative Review and Proposed Clinical Actionability Framework.International journal of general medicine · 2026Review
- Impact of multiplex polymerase chain reaction testing in patients with bacteremia.Microbiology spectrum · 2025Article
- [Efficiency and Usefulness of the Molecular Test 'BiofireAnnals of burns and fire disasters · 2025Article
- Diagnosis and Management of Neonatal Bacterial Sepsis: Current Challenges and Future Perspectives.Tropical medicine and infectious disease · 2024Review
- Rapid Direct Identification of Microbial Pathogens and Antimicrobial Resistance Genes in Positive Blood Cultures Using a Fully Automated Multiplex PCR Assay.Journal of Korean medical science · 2024Article
- Stop in Time: How to Reduce Unnecessary Antibiotics in Newborns with Late-Onset Sepsis in Neonatal Intensive Care.Tropical medicine and infectious disease · 2024Review
- Comparison of 3 diagnostic platforms for identification of bacteria and yeast from positive blood culture bottles.Diagnostic microbiology and infectious disease · 2023Article
- Influence of Multiplex PCR in the Management of Antibiotic Treatment in Patients with Bacteremia.Antibiotics (Basel, Switzerland) · 2023Article
- Multicenter Evaluation of the FilmArray Blood Culture Identification 2 Panel for Pathogen Detection in Bloodstream Infections.Microbiology spectrum · 2023Article
- False Negative Escherichia coli Result from the BioFire FilmArray Blood Culture Identification 2 Panel.Journal of clinical microbiology · 2022Article
- Performance of the BioFire Blood Culture Identification 2 panel for the diagnosis of bloodstream infections.Heliyon · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BioFire blood culture identification (BCID) panel decreases time to pathogen identification and time to optimal antimicrobial therapy. The BioFire blood culture identification 2 (BCID2) panel is an expanded panel with 17 additional targets and resistance genes; however, there are limited data on its impact in pediatric patients. We compared the BioFire BCID2 panel and the BCID panel by assaying BCID2 simultaneously with the current standard of care on 191 consecutive blood culture specimens at Children's Hospital Colorado. The primary outcome was equivalence, measured as percent agreement between the two panels and standard culture. The theoretical reduction in time to optimal therapy was calculated overall, with subanalyses performed on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.